Heart failure & cardiomyopathies
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
Study context
- Population
- Patients with recent myocardial infarction (MI) (3–14 days) and left ventricular (LV) systolic dysfunction280 in modified ITT
- Participants
- 294 patients
- Comparison
- CDR132L vs placebo
- Primary endpoint
- Percentage change in LV end-systolic volume index
- Follow-up
- 6 months
Methodological detailsmultinational, double-blind, placebo-controlled, phase 2
- Multinational
- Double-blind
- Placebo-controlled
- Phase 2
Primary result
As reported in the abstract
- Improved in all groups but no significant difference between CDR132L (5 and 10 mg kg-1) and placebo
- Modified intention-to-treat
Secondary outcomes
LVEF, global longitudinal strain, NT-proBNP
- No significant difference between CDR132L and placebo
Safety
Tolerability and toxicity
- Well tolerated; no hepatic, renal, hematologic or cardiac toxicity signals
Original publication
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial. Nat Med. Published 10 May 2026. doi:10.
Summarised from the published abstract; every number is checked against it